Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curci

Showing results (671-680 of 679) with videos related to

Pageof 68
Sort By:
You have reached the last page of results.This site can display upto 679 results.
Atmospheric Chemistry and Physics|April 12, 2019
Two-scale multi-model ensemble: is a hybrid ensemble of opportunity telling us more?Stefano Galmarini, Ioannis Kioutsioukis, Efisio Solazzo, et al.
Nature Plants|November 18, 2025
Striking convergent selection history of wheat and barley and its potential for breedingMamadou Dia Sow, Cristian Forestan, Caroline Pont, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Plos Biology|December 24, 2003
Transcriptome analysis of mouse stem cells and early embryosAlexei A Sharov, Yulan Piao, Ryo Matoba, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2024
The 10,000-year biocultural history of fallow deer and its implications for conservation policyKaris H Baker, Holly Miller, Sean Doherty, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Plant Biotechnology Journal|July 13, 2026
Durum Wheat cv. Svevo Reference Genome Rel.2.0: A Comprehensive Tool for Wheat GenomicsElisabetta Mazzucotelli, Cristian Forestan, Gina Zastrow-Hayes, et al.
Journal of Personalized Medicine|February 25, 2023
Sex-Related Differences and Factors Associated with Peri-Procedural and 1 Year Mortality in Chronic Limb-Threatening Ischemia Patients from the CLIMATE Italian RegistryEugenio Martelli, Matilde Zamboni, Giovanni Sotgiu, et al.
Pageof 68

Showing results (671-680 of 679) with videos related to

Sort By:
Pageof 68
You have reached the last page of results.This site can display upto 679 results.
Atmospheric Chemistry and Physics|April 12, 2019
Two-scale multi-model ensemble: is a hybrid ensemble of opportunity telling us more?Stefano Galmarini, Ioannis Kioutsioukis, Efisio Solazzo, et al.
Nature Plants|November 18, 2025
Striking convergent selection history of wheat and barley and its potential for breedingMamadou Dia Sow, Cristian Forestan, Caroline Pont, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Plos Biology|December 24, 2003
Transcriptome analysis of mouse stem cells and early embryosAlexei A Sharov, Yulan Piao, Ryo Matoba, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2024
The 10,000-year biocultural history of fallow deer and its implications for conservation policyKaris H Baker, Holly Miller, Sean Doherty, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Plant Biotechnology Journal|July 13, 2026
Durum Wheat cv. Svevo Reference Genome Rel.2.0: A Comprehensive Tool for Wheat GenomicsElisabetta Mazzucotelli, Cristian Forestan, Gina Zastrow-Hayes, et al.
Journal of Personalized Medicine|February 25, 2023
Sex-Related Differences and Factors Associated with Peri-Procedural and 1 Year Mortality in Chronic Limb-Threatening Ischemia Patients from the CLIMATE Italian RegistryEugenio Martelli, Matilde Zamboni, Giovanni Sotgiu, et al.
Pageof 68